Journal
AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 156, Issue 4, Pages 731-736Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2013.05.016
Keywords
-
Categories
Funding
- Senju Pharmaceutical
- Santen Pharmaceutical
- Alcon Japan
- Pfizer Japan
- Kowa
- MSD
- Otsuka Pharmaceutical
- Wakamoto Pharmaceutical
- Bausch Lomb Japan
- Topcon
- Allergan Japan
- Carl Zeiss Japan
- Kowa Company, Ltd., Nagoya, Japan
- Grants-in-Aid for Scientific Research [23592559] Funding Source: KAKEN
Ask authors/readers for more resources
PURPOSE: To identify the optimal dose of a novel Rho kinase inhibitor, K-115, by assessing dose dependency of the intraocular pressure (IOP)-lowering effects and the safety in patients with primary open-angle glaucoma or ocular hypertension. DESIGNS: Multicenter, prospective, randomized, placebo-controlled, double-masked, parallel group comparison clinical study. METHODS: After appropriate washout periods, 210 patients with primary open-angle glaucoma or ocular hypertension were subdivided into 4 groups and were treated with K-115 in concentrations of 0.1%, 0.2%, and 0.4% or placebo twice daily for 8 weeks. The dose response of TOP reduction and the incidence of adverse events by K-115 or placebo were investigated. RESULTS: The mean baseline TOP was between 23.0 and 23.4 mm Hg. The mean TOP reductions of the last visit from baseline were -2.2 mm Hg, -3.4 mm Hg, -3.2 mm Hg, and -3.5 mm Hg, respectively, in the placebo, 0.1%, 0.2%, and 0.4% groups at before instillation (9:00); -2.5 mm Hg, -3.7 mm Hg, -4.2 mm Hg, and -4.5 mm Hg at 2 hours after instillation (11:00); and -1.9 mm Hg, -3.2 mm Hg, -2.7 mm Hg, and -3.1 mm Hg at 8 hours after instillation (17:00). The dose-dependent TOP-lowering effect of K-115 was statistically significant at all time points. Also, conjunctival hyperemia was found in 7 (13.0%) of 54 patients for placebo, 23 (43.4%) of 53 patients for the 0.1% group, 31(57.4%) of 54 patients for the 0.2% group, and 32 (65.3%) of 49 patients for the 0.4% group. CONCLUSIONS: On the basis of this dose-response study, K-115 0.4% has been selected to be the optimal dose and has the potential to be a promising new agent for glaucoma to control 24-hour TOP by twice-daily dosing. ((C) 2013 by Elsevier Inc. All rights reserved.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available